CN Patent

CN120051304A — 室温稳定性羟基脲口服悬浮液

Assigned to Akums Pharmaceutical Co ltd · Expires 2025-05-27 · 1y expired

What this patent protects

本发明提供了一种用于口服施用的液体组合物，其包含有效量的羟基脲。本发明还公开了即用型口服悬浮液形式的液体制剂，其在配药、储存时甚至在重新打开包含悬浮液的容器后在室温下保持稳定。还提供了一种制备制剂和治疗儿童患者的镰状细胞贫血的方法。

USPTO Abstract

本发明提供了一种用于口服施用的液体组合物，其包含有效量的羟基脲。本发明还公开了即用型口服悬浮液形式的液体制剂，其在配药、储存时甚至在重新打开包含悬浮液的容器后在室温下保持稳定。还提供了一种制备制剂和治疗儿童患者的镰状细胞贫血的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN120051304A
Jurisdiction
CN
Classification
—
Expires
2025-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Akums Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.